Vertex Pharmaceuticals Inc / Ma financial data

Symbol
VRTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
50 Northern Avenue, Boston, Massachusetts
State of incorporation
Massachusetts
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 352 % -21%
Quick Ratio 21.8 % +28.5%
Debt-to-equity 31.3 % +2.59%
Return On Assets -2.21 % -112%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 258M shares +0%
Common Stock, Shares, Outstanding 258M shares +0.09%
Entity Public Float 90.7B USD +26.3%
Common Stock, Value, Issued 2.6M USD 0%
Weighted Average Number of Shares Outstanding, Basic 258M shares +0.16%
Weighted Average Number of Shares Outstanding, Diluted 258M shares -0.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 10.3B USD +8.76%
Research and Development Expense 3.2B USD +74.1%
Costs and Expenses 10.7B USD +92.9%
Operating Income (Loss) -349M USD -109%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 215M USD -95%
Income Tax Expense (Benefit) 705M USD -25.1%
Net Income (Loss) Attributable to Parent -490M USD -115%
Earnings Per Share, Basic -1.88 USD/shares -114%
Earnings Per Share, Diluted -2.03 USD/shares -116%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.58B USD -54.9%
Marketable Securities, Current 1.22B USD +12%
Accounts Receivable, after Allowance for Credit Loss, Current 1.66B USD +6.42%
Inventory, Net 915M USD +51.5%
Other Assets, Current 84.3M USD +13.3%
Assets, Current 8.94B USD -35.5%
Deferred Income Tax Assets, Net 2.19B USD +42.1%
Operating Lease, Right-of-Use Asset 570M USD +75.7%
Intangible Assets, Net (Excluding Goodwill) 838M USD +38.8%
Goodwill 1.09B USD 0%
Other Assets, Noncurrent 916M USD +107%
Assets 20.1B USD -1.07%
Accounts Payable, Current 328M USD -9.67%
Employee-related Liabilities, Current 295M USD +19.7%
Accrued Liabilities, Current 2.94B USD +13.2%
Liabilities, Current 3.55B USD +5.82%
Operating Lease, Liability, Noncurrent 587M USD +61.4%
Other Liabilities, Noncurrent 877M USD +15.5%
Liabilities 5.36B USD +9.81%
Accumulated Other Comprehensive Income (Loss), Net of Tax 22.5M USD
Retained Earnings (Accumulated Deficit) 7.65B USD -6.02%
Stockholders' Equity Attributable to Parent 14.8B USD -4.5%
Liabilities and Equity 20.1B USD -1.07%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 1.31B USD +45.2%
Net Cash Provided by (Used in) Financing Activities -358M USD -21.3%
Net Cash Provided by (Used in) Investing Activities -2.14B USD -16.5%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 258M shares +0.09%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.2B USD +1.11%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.59B USD -54.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 10M USD -9.91%
Deferred Tax Assets, Valuation Allowance 267M USD +12.1%
Deferred Tax Assets, Gross 2.43B USD +31.9%
Operating Lease, Liability 382M USD -10.8%
Payments to Acquire Property, Plant, and Equipment 68.4M USD +62.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -428M USD -113%
Lessee, Operating Lease, Liability, to be Paid 436M USD -11.2%
Operating Lease, Liability, Current 33.1M USD -31.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 41.4M USD -6.55%
Lessee, Operating Lease, Liability, to be Paid, Year One 42.1M USD -27.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.02 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 54.4M USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 40.4M USD +0.5%
Deferred Tax Assets, Operating Loss Carryforwards 77.4M USD -27.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1M shares 0%
Unrecognized Tax Benefits 616M USD +34%
Lessee, Operating Lease, Liability, to be Paid, Year Four 36.5M USD -7.36%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 53.5M USD +37.9%
Deferred Tax Assets, Net of Valuation Allowance 2.17B USD +34.9%
Share-based Payment Arrangement, Expense 686M USD +40.3%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%